Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEU-627 Phase 1 in Healthy Volunteers
NCT06900751Phase 1Completed
- Sponsor
- Neuron23
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing NEU-627 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of Single and Multiple Doses of NEU-627 at 10 days. Started Jun 2025; status: completed.
02
Drugs
NEU-627
Beyond the preview
Go deeper on NCT06900751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900751.